The FDA has approved Amgen Inc.'s UCB SA-licensed sclerostin-neutralizing antibody Evenity (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk of breaking a bone. The drug is already approved in Japan and awaits further review in Europe.